Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer

Martijn J. H. G. Simons, Valesca P. Retel, Bram L. T. Ramaekers, Rogier Butter, Joanne M. Mankor, Marthe S. Paats, Joachim G. J. Aerts, Zakile A. Mfumbilwa, Paul Roepman, Veerle M. H. Coupe, Carin A. Uyl-de Groot, Wim H. van Harten, Manuela A. Joore*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1429-1442
Number of pages14
JournalPharmacoeconomics
Volume39
Issue number12
Early online date18 Aug 2021
DOIs
Publication statusPublished - Dec 2021

Keywords

  • OPEN-LABEL
  • PHASE-III
  • 1ST-LINE TREATMENT
  • METASTATIC CANCER
  • CHEMOTHERAPY
  • ERLOTINIB
  • MULTICENTER
  • THERAPIES
  • SURVIVAL
  • ADENOCARCINOMA

Cite this